Photo taken from Raffaele Colombo/Twitter
Oct 2, 2023, 18:10
Raffaele Colombo: ADC history.
Quoting Raffaele Colombo, Principal Scientists at Zyme Works on X/Twitter:
“Maytansine was isolated in the early ‘70s and tested in several clinical trials until 1984. Two ADC payloads derived from it, DM1 and DM4. T-DM1 was approved in 2013 and Mirvetuximab in 2022. But not so easy: 23 other maytansinoid ADCs got discontinued in the past 22 years! Camptothecin and auristatin ADCs for another time. Part of the T-DM1 history, the Refuse To File (RTF) letter for the accelerated approval of T-DM1 in 2010.”
Source: Raffaele Colombo/Twitter.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19